A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma-论文-万方医学网

首页> > A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma

A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma

导出原文传递

翻译打印收藏纠错

第一作者： Ortega Hector

作者： Ortega Hector ^[1] ; Fitzgerald Mary ^[2] ; Raghupathi Kartik ^[3] ; Tompkins Cindy‐ann ; Shen Jinshan ; Dittrich Karen ; Pattwell Caroline ; Singh Dave

作者单位： Medicines Evaluation UnitManchester University Hospital TrustManchester,UK ^[1] Gossamer Bio IncSan Diego,CA,USA ^[2] Pieris PharmaceuticalsBoston,MA,USA ^[3]

关键词 atopic asthma CRTH2 DP2 antagonist eosinophilic asthma prostaglandin D2

发布时间 2022-09-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma

相似文献

同项目论文

相关期刊

检索历史 清除

A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma

相似文献

同项目论文

相关期刊

检索历史清除